Collegium Pharmaceutical, Inc. (COLL) News
Filter COLL News Items
COLL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
COLL News Highlights
- COLL's 30 day story count now stands at 9.
- Over the past 23 days, the trend for COLL's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about COLL are NOV, ASR and TOP.
Latest COLL News From Around the Web
Below are the latest news stories about COLLEGIUM PHARMACEUTICAL INC that investors may wish to consider to help them evaluate COLL as an investment opportunity.
Insider Sell: EVP and General Counsel Shirley Kuhlmann Sells 25,600 Shares of Collegium ...Shirley Kuhlmann, the Executive Vice President and General Counsel of Collegium Pharmaceutical Inc, has recently sold 25,600 shares of the company's stock. |
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 PatentSTOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision affirming the invalidity of Purdue’s ‘961 patent confirms b |
12 Cheap NASDAQ Stocks To BuyIn this piece, we will take a look at the 12 cheap NASDAQ stocks to buy. To skip our overview of one of the world’s largest stock exchanges and some recent financial news, read 5 Cheap NASDAQ Stocks To Buy. Stocks markets have been taking a hammering over the past couple of years amid a […] |
Collegium Announces $25 Million Accelerated Share Repurchase ProgramSTOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized |
Should You Be Worried About Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 5.0% Return On Equity?One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will... |
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Call TranscriptCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Call Transcript November 7, 2023 Collegium Pharmaceutical, Inc. misses on earnings expectations. Reported EPS is $0.53 EPS, expectations were $1.24. Operator: Greetings, and welcome to Collegium Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow […] |
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 EarningsWhile the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
Collegium to Participate in Upcoming Investor ConferencesSTOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences: Jefferies 14th Annual Global Healthcare ConferenceFireside Chat Date and Time: Tuesday, November 14, 2023, at 9:30 a.m. GMT Piper Sandler 35th Annual Healthcare ConferenceFir |
Collegium Reports Third Quarter 2023 Financial Results– Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up 19% Year-over-Year – – Received Extension of Nucynta® Regulatory Exclusivity through July 2026 – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Updated Full Year 2023 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Nov. 07, |
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings GrowthCatalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |